Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 20

NCT ID: NCT01455610 Not yet recruiting - Clinical trials for Adenocarcinoma of Head of Pancreas

Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study

Start date: October 2011
Phase: N/A
Study type: Observational

The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectability of pancreatic head cancer with contrasted-enhanced MDCT and its various post processing techniques, taking operational and pathological records as the gold standard.

NCT ID: NCT01344837 Not yet recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

Start date: January 2100
Phase: N/A
Study type: Observational

This research study is studying biomarkers in blood and tissue samples from patients with uterine cancer. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.

NCT ID: NCT01180153 Not yet recruiting - Clinical trials for Biliary Tract Cancer

Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)

Start date: August 2010
Phase: Phase 2
Study type: Interventional

To evaluate efficacy and safety of S-1 Oxaliplatin (SOX) regimen to patients with unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma.

NCT ID: NCT01131429 Not yet recruiting - Clinical trials for Carcinoma, Non-Small Cell Lung

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Objective: the objective of this study in china is to clarify, whether the overall survival is different between previously untreated stage IIIB/IV lung adenocarcinoma with EGFR mutations receiving first-line erlotinib plus second-line docetaxel/cisplatin and those receiving first-line docetaxel/cisplatin plus second-line erlotinib .